These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38966218)

  • 1. Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study.
    Bassi M; Franzone D; Dufour F; Spacco G; Cresta F; d'Annunzio G; Tantari G; Calevo MG; Castellani C; Minuto N; Casciaro R
    Front Endocrinol (Lausanne); 2024; 15():1347141. PubMed ID: 38966218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
    Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
    Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring.
    van den Heuvel T; Kolassa R; Keuthage W; Kroeger J; Ré R; de Portu S; Vorrink L; Shin J; Castañeda J; Vigersky R; Cohen O
    J Diabetes Sci Technol; 2024 Sep; 18(5):1132-1138. PubMed ID: 36949671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetes.
    Jalilova A; Pilan BŞ; Demir G; Özbaran B; Balkı HG; Arslan E; Köse SG; Özen S; Darcan Ş; Gökşen D
    Eur J Pediatr; 2024 Jul; 183(7):3095-3103. PubMed ID: 38661816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems.
    Bahillo-Curieses P; Fernández Velasco P; Pérez-López P; Vidueira Martínez AM; Nieto de la Marca MO; Díaz-Soto G
    Endocrine; 2024 Nov; 86(2):539-545. PubMed ID: 38814372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 12-Month Real-Life Efficacy of the MiniMed 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.
    Lablanche S; Delagenière J; Jalbert M; Sonnet E; Benichou M; Arnold N; Spiteri A; Le Berre JP; Renard E; Chevalier N; Borot S; Bonnemaison E; Coffin C; Teissier MP; Benhamou PY; Borel JC; Penfornis A; Joubert M; Kessler L
    Diabetes Technol Ther; 2024 Jun; 26(6):426-432. PubMed ID: 38236643
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of advanced hybrid closed loop systems in children with type 1 diabetes younger than 6 years.
    Rapini N; Martino M; Arnaldi C; Deodati A; Anagnostopoulou L; Amodeo ME; Ciampalini P; Pampanini V; Lorubbio A; Tosini D; Cianfarani S; Schiaffini R
    Front Endocrinol (Lausanne); 2024; 15():1382920. PubMed ID: 38836230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time In Tight Range in children and adolescents with type 1 diabetes: A cross-sectional observational single centre study evaluating efficacy of new advanced technologies.
    Schiaffini R; Lumaca A; Martino M; Rapini N; Deodati A; Amodeo ME; Ciampalini P; Matteoli MC; Pampanini V; Cianfarani S
    Diabetes Metab Res Rev; 2024 Jul; 40(5):e3826. PubMed ID: 38824455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the feasibility of time in tight range (TITR) targets with advanced hybrid closed loop (AHCL) use in children and adolescents: A single-centre real-world study.
    Eviz E; Killi NE; Karakus KE; Can E; Gokce T; Yesiltepe Mutlu G; Hatun S
    Diabet Med; 2024 Aug; 41(8):e15333. PubMed ID: 38671595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
    Benhalima K; Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C
    Lancet Diabetes Endocrinol; 2024 Jun; 12(6):390-403. PubMed ID: 38697182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on Glycemia Risk Index and other metrics in type 1 adult patients switching to Advanced Hybrid Closed-Loop systems: a one-year real-life experience.
    Resmini E; Zarra E; Dotti S; Rotondi G; Cornaghi AV; Madaschi S; Cimino E; Massari G; Pezzaioli LC; Buoso C; Sandri M; Girelli A
    Eur J Med Res; 2024 Jul; 29(1):365. PubMed ID: 39004734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes.
    Bassi M; Teliti M; Lezzi M; Iosca A; Strati MF; Carmisciano L; d'Annunzio G; Minuto N; Maggi D
    Front Endocrinol (Lausanne); 2021; 12():802419. PubMed ID: 35116007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort.
    Matejko B; van den Heuvel T; Castaneda J; Arrieta A; Cyranka K; Cohen O; Małecki M; Klupa T
    Diabetes Res Clin Pract; 2024 Oct; 216():111832. PubMed ID: 39173678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy.
    Lepore G; Borella ND; Castagna G; Ippolito S; Bonfadini S; Corsi A; Scaranna C; Dodesini AR; Bellante R; Trevisan R
    Diabetes Technol Ther; 2024 Jan; 26(1):49-58. PubMed ID: 37902785
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Outcomes with MiniMed
    Abraham MB; Smith GJ; Dart J; Davis EA; Jones TW
    Diabetes Technol Ther; 2024 May; 26(5):341-345. PubMed ID: 38215208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes.
    Bassi M; Patti L; Silvestrini I; Strati MF; Ponzano M; Minuto N; Maggi D
    Front Endocrinol (Lausanne); 2023; 14():1099024. PubMed ID: 36777356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.
    Scully KJ; Sherwood JS; Martin K; Ruazol M; Marchetti P; Larkin M; Zheng H; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Wexler DJ; Putman MS
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1444-e1454. PubMed ID: 34850006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Glycemic Outcomes During the MiniMed
    Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
    Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
    [No Abstract]   [Full Text] [Related]  

  • 19. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
    Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
    Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
    Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
    Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.